X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs DR. REDDYS LAB - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD DR. REDDYS LAB WYETH LTD/
DR. REDDYS LAB
 
P/E (TTM) x 27.7 27.2 101.9% View Chart
P/BV x 5.3 2.8 190.9% View Chart
Dividend Yield % 1.3 1.0 126.0%  

Financials

 WYETH LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    WYETH LTD
Mar-13
DR. REDDYS LAB
Mar-16
WYETH LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,0444,383 23.8%   
Low Rs8182,750 29.7%   
Sales per share (Unadj.) Rs298.6920.1 32.4%  
Earnings per share (Unadj.) Rs57.2126.1 45.4%  
Cash flow per share (Unadj.) Rs58.4183.0 31.9%  
Dividends per share (Unadj.) Rs17.0020.00 85.0%  
Dividend yield (eoy) %1.80.6 325.6%  
Book value per share (Unadj.) Rs249.5685.8 36.4%  
Shares outstanding (eoy) m22.72170.61 13.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.13.9 80.5%   
Avg P/E ratio x16.328.3 57.5%  
P/CF ratio (eoy) x15.919.5 81.8%  
Price / Book Value ratio x3.75.2 71.8%  
Dividend payout %29.715.9 187.3%   
Avg Mkt Cap Rs m21,157608,481 3.5%   
No. of employees `0000.521.7 2.3%   
Total wages/salary Rs m40031,874 1.3%   
Avg. sales/employee Rs Th13,787.47,244.4 190.3%   
Avg. wages/employee Rs Th813.01,470.9 55.3%   
Avg. net profit/employee Rs Th2,643.3992.8 266.2%   
INCOME DATA
Net Sales Rs m6,783156,978 4.3%  
Other income Rs m3532,693 13.1%   
Total revenues Rs m7,136159,671 4.5%   
Gross profit Rs m1,61734,587 4.7%  
Depreciation Rs m279,705 0.3%   
Interest Rs m6824 0.7%   
Profit before tax Rs m1,93826,751 7.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6325,237 12.1%   
Profit after tax Rs m1,30121,514 6.0%  
Gross profit margin %23.822.0 108.2%  
Effective tax rate %32.619.6 166.6%   
Net profit margin %19.213.7 139.9%  
BALANCE SHEET DATA
Current assets Rs m6,984118,201 5.9%   
Current liabilities Rs m2,05668,368 3.0%   
Net working cap to sales %72.631.7 228.8%  
Current ratio x3.41.7 196.5%  
Inventory Days Days9960 165.5%  
Debtors Days Days2497 24.7%  
Net fixed assets Rs m24472,265 0.3%   
Share capital Rs m227853 26.6%   
"Free" reserves Rs m5,441111,548 4.9%   
Net worth Rs m5,668117,009 4.8%   
Long term debt Rs m2510,690 0.2%   
Total assets Rs m7,901200,104 3.9%  
Interest coverage x353.333.5 1,055.8%   
Debt to equity ratio x00.1 4.8%  
Sales to assets ratio x0.90.8 109.4%   
Return on assets %16.511.2 148.1%  
Return on equity %22.918.4 124.8%  
Return on capital %34.021.6 157.7%  
Exports to sales %0.246.3 0.5%   
Imports to sales %36.39.0 406.1%   
Exports (fob) Rs m1572,618 0.0%   
Imports (cif) Rs m2,46514,050 17.5%   
Fx inflow Rs m1575,405 0.0%   
Fx outflow Rs m2,67727,115 9.9%   
Net fx Rs m-2,66248,290 -5.5%   
CASH FLOW
From Operations Rs m92340,476 2.3%  
From Investments Rs m317-19,421 -1.6%  
From Financial Activity Rs m-481-17,009 2.8%  
Net Cashflow Rs m7594,046 18.8%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 5.4 209.3%  
FIIs % 7.2 35.3 20.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 30.4 15.3 198.7%  
Shareholders   21,978 75,885 29.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare WYETH LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - JUBILANT LIFE SCIENCES COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS